Biomarkers are measurable indicators of biological or disease-related processes and responses, offering essential insights into health.

Biomarkers can take the form of molecules, genes, cells, hormones, enzymes, or physiological traits, helping to detect, diagnose, and track diseases. They differ from clinical outcome assessments (COAs), which directly measure a person’s feelings, functioning, or survival¹.

Key characteristics of effective biomarkers

For biomarkers to be reliable and valuable, they must possess three essential characteristics to guide accurate diagnoses, effective treatments, and meaningful research².

Sensitivity, specificity, and reproducibility

A biomarker’s sensitivity refers to its ability to accurately detect true positives, such as identifying diseased individuals. A sensitive biomarker minimizes false negatives, ensuring that those with the disease are correctly identified. This is important for conditions where early detection can significantly improve prognosis, such as in cancers or chronic diseases. Sensitivity is essential in screening tests, where the goal is to catch as many cases as possible, even if it leads to some false positives.

Specificity refers to a biomarker’s ability to accurately detect true negatives, excluding healthy individuals. A specific biomarker minimizes false positives, preventing unnecessary treatments or further testing. Specificity is key in diagnostic tests where the objective is to rule out disease in individuals who are healthy or unaffected.

Reproducibility is also vital, ensuring that biomarker results are consistent across different tests, various laboratories, and over time. A reproducible biomarker provides dependable insights, facilitating informed decision-making.

Other key attributes of reliable biomarkers include:

• Easy measurement: A biomarker should be easy to measure, even in small quantities, using available and affordable technology. This ensures that testing can be done frequently and on a scale without significant resource expenditure. Ideally, the biomarker should be detectable in non-invasive or minimally invasive samples (eg, blood, saliva, urine), making it more practical for widespread use in clinical settings.
• Affordability: Reliable biomarkers need to be cost-effective, allowing them to be incorporated into regular clinical practice, particularly in resource-limited settings. The costs of biomarker tests should not outweigh the benefits of early diagnosis, monitoring, or treatment. Affordable testing increases accessibility and ensures that the biomarker can be used globally.
• Consistency across ethnic groups and sex: Biomarkers should consistently and accurately perform across diverse populations, including different ethnic groups and among the same sex. Ensuring broad applicability helps prevent disparities in their effectiveness. It is essential to consider variations in disease susceptibility and biomarker performance across demographics to minimize bias and enhance generalizability.
• Correlation with the severity of damage: A reliable biomarker should correlate well with the severity of the disease or condition it is intended to detect. This allows clinicians to not only diagnose the disease but also to assess its progression or remission. This is important in chronic conditions or diseases with variable progression, such as autoimmune disorders, cancer, or neurodegenerative diseases. Such biomarkers help in monitoring treatment efficacy and adjusting therapeutic interventions accordingly.
• Providing adequate lead time: An effective biomarker should provide sufficient lead time for early intervention before symptoms appear, particularly in diseases where early treatment can significantly alter the course of the condition.
• For example, cancer biomarkers (like prostate-specific antigen for prostate cancer, CA-125 for ovarian cancer)³ that detect the disease before it reaches an advanced stage can dramatically improve survival rates.
• Dynamic response to treatment: A good biomarker should reflect changes in response to treatment, providing real-time insights into patient progress and optimizing therapeutic strategies.
• Clear mechanistic link: Ideally, a biomarker should have a well-understood biological or physiological basis that links it directly to the disease process. This mechanistic understanding ensures that the biomarker is not only useful for diagnosis but also provides insights into disease pathophysiology, potentially informing therapeutic targets.
• Regulatory approval and clinical validation: A biomarker must undergo rigorous validation and approval from regulatory bodies, such as the FDA or EMA, to be reliable in clinical practice. This ensures that the biomarker performs as expected under real-world conditions and meets established standards for accuracy, sensitivity, and specificity.

Types of biomarkers

Biomarkers are broadly categorized based on their functional roles, clinical applications, and biological origin.

Biomarkers categorized by biological origin

Biomarkers are derived from various biological sources, reflecting the complexity and diversity of the human body.

Molecular biomarkers

Molecular biomarkers are derived from specific molecules, providing detailed information about biological processes. They are also known as “signature molecules.” Proteomic signatures, transcriptional alterations, epigenetic signatures, and germline or somatic genetic variations are a few examples. These markers are based on biomolecules, such as proteins and nucleic acids, which can be found in tissue samples taken by tumor biopsy or, in a more straightforward and non-invasive manner, in blood (or serum or plasma), saliva, buccal swabs, stool, urine, etc⁴.

Genetic biomarkers

Genetic biomarkers are DNA or RNA sequences that can help identify diseases or indicate a person’s susceptibility to disease and response to therapeutic or other interventions. These include gene mutations, single-nucleotide polymorphisms (SNPs), and other genetic variations. For example, mutations in the BRCA1 and BRCA2 genes are well-known genetic biomarkers for breast and ovarian cancer risk⁵.

Other examples include APC gene mutations for familial adenomatous polyposis (FAP), which can be used to identify lung cancer, and genetic variants associated with sickle cell anemia and cystic fibrosis⁶. These biomarkers help identify individuals with increased disease risk, enabling early interventions.

Expression quantitative trait loci (eQTLs), genomic regions that regulate gene expression, can be used as biomarkers to identify the genetic cause of a disease in an individual patient and determine and explain relative risks for individuals based on their genetic risks.

For example, in Alzheimer’s disease, eQTLs analyses reveal how variations affect APOE gene expression. The APOE ε4 allele is the most significant genetic risk factor for Alzheimer’s disease, while the ε2 allele is considered protective⁷. In addition, various RNA molecules, including messenger RNA (mRNA) and extracellular RNAs, are increasingly used as non-invasive biomarkers. Detectable in multiple biofluids, extracellular RNAs are emerging as valuable tools for early cancer detection, monitoring tumor progression, and predicting treatment responses.

Epigenetic biomarkers

Epigenetic biomarkers focus on gene expression changes that are influenced by environmental factors rather than genetic mutations. These markers provide valuable insights into how environmental exposures, lifestyle choices, and even aging can affect gene activity without altering the DNA sequence. Epigenetic modifications, such as DNA methylation, histone modification, and RNA-based regulation, play significant roles in disease development and progression.

DNA methylation is one of the most widely studied epigenetic changes⁸, where the addition of methyl groups to the DNA molecule can silence or activate genes. In cancer, aberrant DNA methylation patterns can lead to the silencing of tumor suppressor genes or the activation of oncogenes, making it a vital area of research for early cancer detection and prognosis.

Histone modifications, which involve changes to the proteins around which DNA is wrapped, can also profoundly affect gene expression. Alterations in histone acetylation or methylation are linked to various neurological disorders, including Alzheimer’s disease and other neurodegenerative conditions. These modifications influence chromatin structure and, consequently, gene accessibility, providing a mechanism for regulating brain function and cellular activity.

MicroRNAs (miRNAs) and other non-coding RNAs are another group of epigenetic biomarkers that have garnered significant attention. These small RNA molecules play key roles in regulating gene expression by binding to messenger RNAs (mRNAs) and preventing their translation. Specific miRNA expression profiles have been associated with various cancers, cardiovascular diseases, and neurological disorders⁹.

For example, the upregulation of certain miRNAs (like let-7, miR-15/16, miR-34, and miR-200) can be indicative of tumorigenesis, while their downregulation might suggest a loss of cell function¹⁰. Additionally, emerging classes of small RNAs, such as piwi-interacting RNAs (piwiRNAs), short non-coding RNAs, long non-coding RNAs (lncRNAs), and circular RNAs, are expanding the repertoire of epigenetic biomarkers for disease detection and progression.

These epigenetic biomarkers offer significant promise in understanding complex diseases and tailoring more personalized, targeted therapies.

Protein biomarkers

Protein biomarkers, such as antibodies and enzymes, indicate changes in protein expression or function, translating to the presence, stage, and progression of a disease.

Prostate-specific antigen (PSA) is a widely used biomarker for prostate cancer¹¹. Elevated PSA levels can indicate the presence of prostate cancer, although it is not specific to cancer alone, as benign prostate conditions can also increase PSA levels.

Other examples include CA-125 for ovarian cancer and C-reactive protein (CRP) for inflammation and cardiovascular disease^12,13. These biomarkers aid diagnosis, monitor disease progression, and track treatment response.

Metabolic biomarkers

Metabolic biomarkers measure metabolic products, like glucose and lipids, to assess metabolic health¹⁴. Blood glucose levels are an important biomarker for diabetes management¹⁵. For instance, elevated glucose levels indicate insulin resistance or inadequate glycemic control, while low levels suggest hypoglycemia.

Lipid profiles are used to assess cardiovascular disease risk by measuring levels of cholesterol and other lipids in the blood. High levels of low-density lipoprotein (LDL) cholesterols and triglycerides, and low levels of high-density lipoprotein (HDL) cholesterols are associated with an increased risk of heart disease, stroke, and other cardiovascular conditions.

Lactate levels^16,17, which indicate tissue oxygenation and metabolism, are essential biomarkers for monitoring tissue hypoxia, particularly in conditions such as shock, sepsis, or cancer. Elevated lactate levels often signal a lack of oxygen in tissues and can be used to monitor disease progression or response to treatment.

Physiological biomarkers

Physiological biomarkers reflect functional changes in organs or systems. These biomarkers are essential for monitoring disease progression and treatment efficacy.

Cardiovascular biomarkers

Cardiovascular biomarkers reflect the health and functioning of the heart and blood vessels. These markers are essential for diagnosing heart disease, monitoring cardiovascular risk, and assessing the effectiveness of treatments¹⁸.

• Blood pressure: This is important for diagnosing hypertension and assessing cardiovascular risk.
• Heart rate: This indicates conditions such as arrhythmia or heart failure.
• Cardiac output: This is important for assessing heart function.
• Heart rate variability (HRV): The variation in time intervals between heartbeats reflects autonomic nervous system function and cardiovascular health.

Respiratory biomarkers

Respiratory biomarkers help assess lung function and the efficiency of oxygen exchange, which is important for diagnosing respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and sleep apnea.

• Oxygen saturation (SpO₂): A vital marker for monitoring oxygen levels in patients with respiratory or cardiac problems.
• Respiratory rate: This phenomenon acts as an indicator of lung health and function.
• Peak expiratory flow rate: Measures how fast a person can exhale air, often used to monitor conditions like asthma.
• Lung volumes (eg, FEV₁/FVC): Spirometry tests that assess lung function by measuring the volume of air exhaled, helping diagnose obstructive and restrictive lung diseases.

Neurological biomarkers

Neurological biomarkers provide insights into brain health, helping to monitor neurodegenerative diseases, brain injury, and psychiatric conditions.

• Electroencephalography (EEG) signals: Electrical activity of the brain used in diagnosing epilepsy and other neurological disorders.
• Brain-derived neurotrophic factor (BDNF): A protein that supports brain function and whose levels are often linked to cognitive function and neurological diseases such as depression and Alzheimer’s disease.

Renal biomarkers

Renal biomarkers indicate the health of the kidneys and are essential for diagnosing renal diseases, assessing kidney function, and managing chronic kidney disease (CKD).

• Glomerular filtration rate (GFR): A key measure of kidney function that assesses the rate at which the kidneys filter blood.
• Serum creatinine: A waste product in the blood, elevated levels may indicate kidney dysfunction.
• Blood urea nitrogen (BUN): A measure of nitrogen in the blood, which can increase in cases of kidney disease or dehydration.

Hematological biomarkers

Hematological biomarkers provide critical information about blood health, including the presence of anemia, infections, or blood disorders.

• Hemoglobin levels: A protein present in red blood cells responsible for oxygen transport, with low levels indicating anemia.
• Red and white blood cell counts: These counts are used to diagnose anemia, infection, or blood-related diseases.
• Hematocrit: The percentage of blood volume made up of red blood cells, helping assess conditions like anemia or dehydration.
• Platelet counts: Platelets are pivotal for blood clotting; abnormal levels can indicate clotting disorders or bone marrow issues.

Endocrine biomarkers

Endocrine biomarkers provide insight into hormone levels, which regulate various physiological processes and are essential for diagnosing endocrine disorders.

• Thyroid-stimulating hormone (TSH): A key regulator of thyroid function, elevated or decreased levels can indicate thyroid disorders such as hypothyroidism or hyperthyroidism.
• Cortisol: Known as the “stress hormone,” its levels can indicate stress response, adrenal function, and disorders like Cushing’s disease.
• Estrogen: An important hormone for reproductive health, with imbalances linked to conditions like polycystic ovary syndrome (PCOS) and menopause.
• Follicle-stimulating hormone (FSH): Key for reproductive health; elevated levels are associated with menopause or infertility.
• Testosterone: A critical hormone for male health, low levels may indicate testosterone deficiency or other endocrine disorders.

Immune system biomarkers

Immune biomarkers help assess the immune response and inflammation in the body, aiding the diagnosis of autoimmune diseases, infections, and inflammatory conditions.

• C-reactive protein (CRP): A marker of systemic inflammation, elevated levels are associated with conditions such as cardiovascular disease, arthritis, and infections.
• Interleukins: Proteins that mediate immune responses, with specific interleukins linked to diseases like rheumatoid arthritis (IL-6) and inflammatory bowel disease (IL-1β and IL-6)¹⁹.
• Tumor necrosis factor-alpha (TNF-α): A cytokine involved in systemic inflammation, elevated levels are found in autoimmune diseases and inflammatory conditions.

Musculoskeletal biomarkers

Musculoskeletal biomarkers are used to assess bone and muscle health, playing a key role in the diagnosis of osteoporosis, muscle damage, and related conditions.

• Bone density estimates: Help diagnose osteoporosis and assess fracture risk by measuring bone mass.
• Creatine kinase levels: An enzyme released during muscle damage, elevated levels can indicate muscle injury or diseases like muscular dystrophy.
• Markers of bone turnover: Substances that reflect the rate of bone formation(procollagen type 1 N-propeptide (P1NP), osteocalcin, procollagen type 1 C-propeptide (P1CP), and total and bone-specific alkaline phosphatase (ALP)) and resorption (carboxy-terminal cross-linked telopeptide of type 1 collagen (CTX-1), the amino-terminal cross-linked telopeptide of type 1 collagen (NTX-1), hydroxyproline, pyridinoline, tartrate-resistant acid phosphatase 5b, and deoxypyridinoline), are important for monitoring osteoporosis and metabolic bone diseases²⁰.

Gastrointestinal biomarkers

Gastrointestinal biomarkers provide information about digestive health and the presence of gastrointestinal diseases such as inflammatory bowel disease (IBD), liver diseases, and gastrointestinal cancers.

• Fecal calprotectin: A marker of inflammation in the intestines, used to diagnose and monitor IBD such as Crohn’s disease and ulcerative colitis.
• Liver enzymes: Including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), elevated levels are indicative of liver damage or disease.
• Bilirubin levels: Elevated bilirubin can indicate liver disease, bile duct obstruction, or hemolysis.

Histologic biomarkers

Histologic biomarkers analyze tissue composition and cellular abnormalities.

Tissue-based markers

Tissue-based markers provide valuable information about disease mechanisms. The results of tissue biopsies are essential for diagnosing cancer. They offer details on histopathological characteristics such as tumor grade, margins, and invasion patterns. Histopathological examination of liver tissue helps diagnose fibrosis, and immunohistochemistry assesses protein expression^16,17.

Similarly, biomarkers like Lewy bodies in Parkinson’s disease or amyloid plaques in Alzheimer’s disease are found in brain tissue obtained through post-mortem or biopsy, which sheds light on the pathophysiology and stage of the disease. These biomarkers aid decisions about diagnosis, prognosis, and treatment. These biomarkers aid diagnosis, prognosis, and treatment decisions.

Radiographic biomarkers

Radiographic biomarkers utilize medical imaging techniques.

Imaging-based markers

Imaging-based markers offer anatomical and functional insights. They can indicate normal or abnormal biological processes, disease, or responses to treatment. Examples include tissue features like calcium deposition and perfusion, PET-SUV metrics, and molecular imaging biomarkers like PD-L1 expression²¹. These biomarkers can be qualitative or quantitative and are derived from various imaging modalities like X-rays, CT, MRI, and PET.

MRI scans diagnose joint and musculoskeletal disorders, blood flow in tissues, changes in tumor dimensions, etc., while CT scans detect lung cancer and are used for coronary calcium scoring for cardiovascular risk. PET scans evaluate brain function and neurodegenerative diseases. These biomarkers are non-invasive, provide real-time insights, capture whole-organ or system-wide information, and thus enhance diagnosis, monitoring, and treatment planning.

Microbial biomarkers

Microbial biomarkers identify specific microorganisms or their products. These include molecular and genomic information that can be used to identify microorganisms, genes, and pathways; diagnose and forecast infectious diseases; influence host immunity; look at how microbes and hosts interact; associate microbial consortia with illness; and assess how well a treatment works. Bacterial 16S rRNA gene sequencing analyzes the gut microbiome. Viral load measurements monitor HIV and hepatitis²². Fungal biomarkers diagnose invasive aspergillosis²³.

Immunological biomarkers

Immunological biomarkers assess immune system responses. Autoantibody tests diagnose autoimmune diseases²⁴. These biomarkers often include cytokines, chemokines, cell surface proteins, autoantibodies, and other immune-related factors. Cytokine profiling evaluates inflammation and immune function²⁵. Immunophenotyping guides cancer immunotherapy²⁶.  For example, levels of certain autoantibodies, such as anti-nuclear antibodies (ANA), can indicate autoimmune conditions like lupus.

Environmental biomarkers

Environmental biomarkers detect exposure to toxins, pollutants, and other environmental stressors. They are broadly of three types, including biomarkers of exposure (indicating exposure to a contaminant), effect (exhibiting biological response to that exposure), and susceptibility (demonstrating potential sensitivity of an individual to a specific contaminant).

• Biomarkers of exposure reflect direct contact with harmful substances, such as heavy metals or chemicals. For example, heavy metal testing can identify exposure to toxins like lead, arsenic, cadmium, and mercury, which are associated with neurological and developmental harm²⁷.
• Biomarkers of effect showcase the biological responses triggered by exposure, such as changes in gene expression or cell function, often indicating early signs of disease or damage. Pesticide biomarkers are commonly used to monitor the health of agricultural workers, indicating the physiological impact of pesticide exposure.
• Common pesticide biomarkers include urinary metabolites (eg, folpet, tebuconazole). Additionally, cholinesterase (essential for nerve function) inhibition reveals exposure to pesticides like organophosphates and carbamates²⁸, while altered microRNAs (eg, miR-199a-5p) reflect chronic exposure. Biomarkers of susceptibility assess an individual’s genetic or environmental vulnerability to specific contaminants, helping to identify those at higher risk of adverse health outcomes.

Common environmental biomarkers include urinary metabolites of pollutants, inflammatory cytokine levels, DNA adducts (markers of DNA damage), and oxidative stress markers, all of which are important for evaluating the effects of air pollution, industrial chemicals, and other environmental hazards on health. These biomarkers aid in environmental health studies and regulatory assessments, helping prevent disease linked to environmental factors.

Digital biomarkers

Digital biomarkers leverage data from wearable devices, smartphone apps, and sensor devices.

Data from wearable devices

Data from wearable devices track physiological parameters. Heart rate monitors assess cardiovascular health, step counters measure physical activity, and sleep trackers evaluate sleep quality. Digital biomarkers offer a non-invasive, continuous way to track health, enabling personalized care and early detection of health issues.

Smartphone-based measurements

Smartphone-based measurements provide valuable health insights. Apps track physical activity, nutrition, and stress. Mobile electrocardiography (ECG) analyzes cardiac rhythm, and mobile-based cognitive function assessments evaluate neurological health²⁹.

Sensor devices can detect specific biomarkers from body fluids like sweat, saliva, or blood. For instance, continuous glucose monitors are widely used to track glucose levels and help in diabetes management.

Biomarkers classified by clinical application

Biomarkers can be categorized based on their clinical utility, reflecting their diverse roles in patient care.

Diagnostic biomarkers

Diagnostic biomarkers aid in early disease detection, accurate diagnosis, staging, and grading of diseases, and monitoring disease progression. PSA is a well-known diagnostic biomarker for prostate cancer¹¹. Other examples include glucose levels for diabetes diagnosis, troponin for myocardial infarction (heart attack), and lung function tests for chronic obstructive pulmonary disease (COPD)^30,31.

Prognostic biomarkers

Prognostic biomarkers help predict disease recurrence or progression in patients who have the disease or medical condition of interest, identify high-risk patients, enhance patient stratification, and inform treatment decisions. The cancer staging system (TNM), circulating lncRNAs, number of lymph nodes positive for tumor cells, and presence of metastasis are a few biomarkers for cancer prognosis³².

Cardiovascular risk scores, such as the Framingham risk score, estimate an individual’s risk of developing cardiovascular disease³³. Genetic markers for inherited diseases, like BRCA1 and BRCA2, also provide prognostic information⁵.

Predictive biomarkers

Predictive biomarkers guide targeted therapies, identify responders and non-responders, optimize treatment regimens, and reduce adverse reactions. KRAS mutation status is a predictive biomarker for colorectal cancer treatment, while HER2 status guides breast cancer treatment^34,35. BRAF mutation status informs treatment decisions for melanoma, and pharmacogenomic markers predict drug metabolism^36,37.

Pharmacodynamic biomarkers

Pharmacodynamic biomarkers monitor treatment response, adjust dosage and regimen, enhance patient safety, and improve treatment outcomes. Additionally, they help in biosimilar drug development. For instance, blood pressure monitoring is essential for hypertension treatment, while HbA1c levels track diabetes management³⁸. Liver function tests detect hepatotoxicity, and tumor shrinkage assesses cancer treatment efficacy^39,40.

Safety biomarkers

Safety biomarkers identify potential toxicities, monitor adverse effects, guide dose adjustment, and enhance patient safety. Liver enzyme tests detect hepatotoxicity, kidney function tests identify nephrotoxicity, and complete blood counts (CBC) monitor hematotoxicity. Electrocardiography (ECG) assesses cardiotoxicity^39,41,42.

Susceptibility/risk biomarkers

Susceptibility biomarkers identify high-risk individuals, guide preventive measures, enhance screening and early detection, and inform lifestyle modifications. Genetic markers for inherited diseases, such as sickle cell anemia, predict disease risk⁴³. Lipid profiles assess cardiovascular disease risk, and body mass index (BMI) evaluates obesity-related risks.

Examples of biomarkers and their applications

Biomarkers play a vital role in disease diagnosis, monitoring, and treatment. The following examples illustrate the diverse applications of biomarkers in various diseases.

Cardiovascular disease biomarkers

Cardiovascular disease biomarkers are essential for diagnosing and managing conditions like heart attacks, heart failure, and atherosclerosis. These biomarkers help identify individuals at risk, monitor disease progression, and guide treatment decisions.

Troponin

Troponin is a protein found in cardiac muscle cells. Elevated troponin levels in the bloodstream indicate myocardial infarction (heart attack). Troponin testing helps diagnose acute coronary syndromes and guides timely interventions³⁶.

BNP

Brain natriuretic peptide (BNP) is a hormone secreted by the heart in response to increased ventricular stretch and pressure⁴⁴. Elevated BNP levels indicate heart failure, helping clinicians diagnose and manage this condition.

CRP

C-reactive protein (CRP) is a biomarker for inflammation, which contributes to cardiovascular disease⁴⁵. Elevated CRP levels indicate increased cardiovascular risk, helping clinicians identify individuals who may benefit from preventive measures.

LDL cholesterol

LDL cholesterol, often referred to as “bad” cholesterol, is a biomarker for atherosclerosis and cardiovascular disease risk⁴⁶. Monitoring LDL cholesterol levels helps clinicians assess cardiovascular risk and guide lipid-lowering therapies.

Cancer biomarkers

Cancer biomarkers aid in the early detection, diagnosis, and monitoring of various cancers. These biomarkers help identify individuals at risk, diagnose cancer at an early stage, and guide targeted therapies.

PSA

PSA is a protein produced by prostate cells. Elevated PSA levels may indicate prostate cancer, making PSA testing a valuable tool for screening and early detection¹¹.

CA-125

Cancer antigen 125 (CA-125) is a biomarker for ovarian cancer. Elevated CA-125 levels help monitor disease progression and treatment response, guiding clinicians in adjusting therapies¹².

HER2

Human epidermal growth factor receptor 2 (HER2) is a biomarker for breast cancer. HER2-positive breast cancers respond to targeted therapies, making HER2 testing crucial for guiding treatment decisions³⁵.

Diabetes biomarkers

Diabetes biomarkers help diagnose and manage diabetes mellitus. These biomarkers assess glucose control, insulin production, and disease complications.

HbA1c

Hemoglobin A1c (HbA1c) measures average blood glucose levels over the past 2–3 months. HbA1c testing helps diagnose diabetes, monitor glucose control, and adjust treatment plans³⁸.

C-peptide

C-peptide is a biomarker for insulin production⁴⁷. Measuring C-peptide levels helps diagnose diabetes, assess insulin function, and guide treatment decisions.

FPG

Fasting plasma glucose (FPG) measures glucose levels after an overnight fast, diagnosing diabetes (≥126 mg/dL) and monitoring glucose control. FPG testing also assesses insulin sensitivity⁴⁸.

Neurodegenerative disease biomarkers

Neurodegenerative disease biomarkers help diagnose and monitor conditions like Alzheimer’s disease and Parkinson’s disease. These biomarkers identify disease-specific changes in the brain.

Amyloid-beta and tau proteins

Amyloid-beta and tau proteins are established biomarkers for Alzheimer’s disease⁴⁹. Elevated levels indicate amyloid plaque accumulation and neurofibrillary tangle formation.

Neurofilament light chain

Neurofilament light chain (NfL) is a biomarker for neuroaxonal damage. Elevated NfL levels are observed in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.

Infectious disease biomarkers

Infectious disease biomarkers enable rapid diagnosis and monitoring of infections. These biomarkers help identify pathogens, quantify infection levels, and guide treatment decisions.

Polymerase chain reaction (PCR) testing

PCR testing detects specific pathogens, allowing for targeted treatment. Biomarkers like IFI27 can identify viral infections early, while PCR confirms the presence of specific pathogens.

Viral load measurements

Viral load measurements quantify infection levels in patients²². This information guides antiviral therapy and monitors treatment response.

Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) is one of the most used tests for COVID-19.

Antibody testing

Antibody testing identifies immune responses to infections and acts as a biomarker by detecting the presence of specific antibodies in the blood of an individual, which can indicate recent or past exposure to a disease-causing pathogen. The antibodies themselves serve as markers for the presence of a specific disease or condition.

This approach is used for the diagnosis of infections such as COVID-19, HIV, certain cancers, and autoimmune diseases like rheumatoid arthritis. This information aids in diagnosis, vaccination strategies, and monitoring treatment efficacy.

Applications of biomarkers in medicine and research

Biomarkers play a vital role in various aspects of medicine and research, transforming the way diseases are diagnosed, treated, and prevented. Their applications are diverse, ranging from disease diagnosis and monitoring to personalized medicine and environmental health.

Disease diagnosis and monitoring

Biomarkers enable early detection and ongoing monitoring of diseases, revolutionizing patient care¹. They facilitate timely interventions, improving disease outcomes. In Alzheimer’s disease, biomarkers like amyloid-beta and tau proteins facilitate early diagnosis and monitoring⁴⁹. Similarly, cardiovascular disease biomarkers such as troponin and C-reactive protein enable timely interventions.

Early detection and ongoing monitoring

PSA testing, for instance, helps diagnose and monitor prostate cancer. Regular monitoring of PSA levels aids in assessing treatment efficacy and detecting potential recurrence. This enables clinicians to adjust treatment plans and improve patient outcomes. Biomarkers also aid in monitoring disease progression, allowing for swift adjustments to treatment strategies.

Personalized medicine and treatment selection

Biomarkers customize treatments by identifying responsive patients. Predictive biomarkers analyze genetic markers, tailoring treatments to individual needs.

Customizing treatments with predictive biomarkers

By identifying genetic variations, clinicians can predict treatment response and optimize therapy.

For instance, HER2 is a predictive biomarker for breast cancer, matching patients with targeted therapies³⁵. KRAS mutation analysis guides colorectal cancer treatment, ensuring effective therapy³⁴. In non-small-cell lung cancer, EGFR mutations guide the use of tyrosine kinase inhibitors such as erlotinib and gefitinib, and ALK rearrangements indicate responsiveness to crizotinib.

BRAF V600E mutations in melanoma patients predict positive responses to vemurafenib, and BRCA1/2 mutations in ovarian and pancreatic cancers suggest sensitivity to PARP inhibitors. Additionally, BCR–ABL fusion genes in chronic myeloid leukemia are targeted by tyrosine kinase inhibitors like imatinib, and PML/RARα fusion in acute promyelocytic leukemia responds to all-trans-retinoic acid and arsenic trioxide therapy⁵⁰.

These biomarkers exemplify the integration of molecular diagnostics into personalized medicine, enabling clinicians to select the most effective therapies based on individual genetic profiles.​

Clinical trials and drug development

Biomarkers streamline clinical trials and drug development. They identify suitable participants and monitor treatment efficacy.

Patient selection and treatment monitoring

Biomarkers track tumor response and disease progression in oncology trials⁵¹. This enables researchers to evaluate new therapies efficiently and make informed decisions. Biomarkers also facilitate the development of targeted therapies.

Environmental health and exposure

Biomarkers assess exposure to environmental toxins or pollutants⁵². They detect exposure to harmful substances, informing public health policies.

Public health applications

For instance, lead levels in the blood indicate environmental exposure⁵³. Biomarkers track the effectiveness of interventions aimed at reducing exposure. This enables policymakers to develop targeted strategies for mitigating environmental health risks.

Agricultural and veterinary applications

Biomarkers advance disease prevention in agriculture and veterinary science. They diagnose and monitor diseases in animals and plants.

Research applications in animal and plant health

Biomarkers play a pivotal role in advancing disease prevention and management in agriculture and veterinary science.

In veterinary medicine, they serve as essential tools for diagnosing and monitoring animal health, detecting conditions such as bovine viral diarrhea⁵⁴, and assessing factors like antibiotic resistance and nutrient digestion capabilities. Molecular biomarkers, including specific proteins and microRNAs, are utilized to identify early disease stages, enabling timely interventions and improving treatment outcomes.​

In agriculture, biomarkers are instrumental in enhancing crop resilience and productivity. They assist in breeding disease-resistant plant varieties by identifying genetic markers associated with stress tolerance.

For instance, the detection of specific proteins and metabolites can indicate a plant’s response to abiotic stresses like drought or salinity, facilitating the development of stress-tolerant crops. Additionally, biomarkers enable early detection of plant diseases, allowing for targeted interventions that minimize yield losses and reduce reliance on chemical pesticides⁵⁵.​

Furthermore, the integration of advanced technologies, such as imaging sensors and biosensors, enhances the precision and efficiency of biomarker detection in both fields. These innovations contribute to sustainable farming practices and improved animal health management, underscoring the significance of biomarkers in modern agriculture and veterinary medicine.

Challenges and limitations in biomarker research

Biomarker research faces several challenges that hinder its progress and effectiveness despite its potential to revolutionize disease diagnosis and treatment⁵⁶.

Validation and standardization

Ensuring the accuracy and reliability of biomarkers is pivotal for their adoption in clinical practice.

Importance of consistent results and regulatory standards

Consistent results and regulatory standards are essential for biomarker validation⁵⁷. Variability in biomarker measurements can lead to inconsistent results, making standardization critical. Regulatory agencies such as the FDA establish guidelines for biomarker validation, ensuring clinical utility.

For instance, the FDA’s biomarker qualification program facilitates biomarker development by providing a framework for qualifications. Additionally, organizations like the National Cancer Institute’s Early Detection Research Network (EDRN) promote standardization through biomarker validation pipelines⁵⁸.

Biological variability and complexity

Biomarkers must account for individual differences and complex biological systems.

Individual differences in biomarker expression

Genetic, environmental, and lifestyle factors influence biomarker expression, leading to individual variations⁵⁹. Accounting for these variations and the use of personalized cutoffs ensure accurate biomarker interpretation. Research has shown that genetic variations affect biomarker expression in cancer (eg, HER2 in breast cancer) and cardiovascular disease (eg, cholesterol levels). Furthermore, biological complexity poses challenges. Biomarkers interact with multiple pathways, making it difficult to distinguish between disease-specific and non-specific changes.

Ethical and privacy considerations

Digital biomarkers, while offering immense potential for advancing healthcare, raise important ethical and privacy concerns. These considerations include:

Use of digital biomarkers and data security

Digital biomarkers require robust security measures to protect personal health data from wearable devices and mobile health applications. Ensuring data protection, informed consent, and addressing ethical concerns is critical, particularly regarding data ownership and control, confidentiality and anonymity, and potential biases in algorithmic decision-making.

Future perspectives on biomarkers

The field of biomarkers is rapidly evolving, driven by cutting-edge technologies and innovative approaches. These advancements hold immense potential for transforming disease diagnosis, treatment, and prevention.

Innovations and trends

Emerging technologies transform biomarker research, enabling more accurate and efficient discovery. Multi-omics approaches, liquid biopsies, and artificial intelligence are at the forefront of this revolution.

Multi-omics approaches

Integrating genomics, proteomics, and metabolomics enhances biomarker discovery⁶⁰. This comprehensive approach provides a deeper understanding of biological systems, revealing complex interactions between genes, proteins, and metabolites. By analyzing these interactions, researchers can identify potential biomarkers for various diseases, including cancer and neurological disorders.

In ovarian cancer research, for instance, the combination of genomic and transcriptomic sequencing with proteomic and metabolomic analyses has led to the identification of novel biomarkers and molecular subtypes, enhancing early diagnosis and personalized treatment strategies⁶¹.

Similarly, in stroke research, integrating data from various omics layers has facilitated the identification of candidate biomarkers and therapeutic targets, offering insights into stroke pathogenesis and aiding in the development of precision medicine approaches⁶².

Liquid biopsies

Liquid biopsies revolutionize cancer diagnosis with non-invasive testing. Circulating tumor DNA (ctDNA) analysis enables early detection, monitoring, and personalized treatment⁶³. Liquid biopsies also show promise in detecting other diseases, such as cardiovascular and infectious diseases, making them a valuable tool in preventive medicine.

Artificial intelligence and machine learning

Artificial intelligence (AI) and machine learning accelerate biomarker identification and analysis⁶¹. AI-driven algorithms rapidly screen large datasets, identify novel biomarker combinations, and enhance predictive accuracy.

For instance, the application of AI in immuno-oncology, analyzed genomic, proteomic, radiomic, and pathomic data to identify predictive biomarkers for immune checkpoint inhibitor efficacy across various cancers, including non-small-cell lung cancer and melanoma⁶².  By leveraging these technologies, researchers can uncover complex patterns and relationships, and analyze scientific literature, leading to breakthroughs in biomarker discovery.

The role of biomarkers in advancing personalized medicine

Biomarkers drive personalized medicine by enabling early disease detection and tailored treatments. By identifying individuals at risk, biomarkers enable targeted therapies and also facilitate monitoring of treatment efficacy, allowing healthcare providers to adjust treatment plans accordingly⁶³.

FAQs

What are some examples of susceptibility/risk biomarkers?

Examples of susceptibility or risk biomarkers include BRCA1/2 for breast and ovarian cancer risk, APOE for Alzheimer’s disease risk, and LDL cholesterol for cardiovascular disease risk. Additionally, genetic markers can identify individuals at risk for conditions like cystic fibrosis.

How do diagnostic biomarkers differ from prognostic biomarkers?

Diagnostic biomarkers identify specific diseases, whereas prognostic biomarkers predict disease outcomes and progression. For instance, PSA is a diagnostic biomarker for prostate cancer, while CRP serves as a prognostic biomarker for cardiovascular disease severity.

What is the role of biomarkers in clinical trials?

Biomarkers play a crucial role in clinical trials by identifying suitable participants, monitoring treatment efficacy, assessing safety, and enabling personalized treatment approaches. This helps researchers evaluate treatment effectiveness and make informed decisions.

What are some common tumor biomarkers and the cancers they are associated with?

Common tumor biomarkers include PSA for prostate cancer, CA-125 for ovarian cancer, HER2 for breast cancer, CEA for colorectal cancer, and AFP for liver cancer. These biomarkers aid in diagnosis, monitoring, and treatment planning.

How do molecular biomarkers differ from physiological biomarkers?

Molecular biomarkers measure specific biomolecules, such as genes or proteins, while physiological biomarkers measure bodily functions, like blood pressure or heart rate. This distinction allows researchers to target specific biological processes.

References

1. Aronson, J. K., Ferner, R. E. Biomarkers—a general review. Current protocols in pharmacology. 76(1), 9-23 (2017).5. James, C. R., Quinn, J. E., Mullan, P. B., et al. BRCA1, a potential predictive biomarker in the treatment of breast cancer. The oncologist. 12(2), 142-150 (2007).
2. Liu, F., Lu, X., Zhou, X. et al. APC gene promoter methylation as a potential biomarker for lung cancer diagnosis: A meta‐analysis. Thoracic cancer. 12(21), 2907-2913 (2021).
3. Serrano-Pozo, A., Das, S., Hyman, B. T., et al. APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches. The Lancet Neurology. 20(1), 68–80 (2021).
4. Wen, K. X., Milic, J., El-Khodor, B., et al. The role of DNA methylation and histone modifications in neurodegenerative diseases: a systematic review. PLoS One. 11(12), e0167201 (2016).
5. Alevizos, I., Alexander, S., Turner, R. J. et al. MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren’s syndrome. Arthritis & rheumatism. 63(2), 535-544 (2011).
6. Otmani, K., Lewalle, P., et al. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: Mechanism of deregulation and clinical implications. Frontiers in Oncology. 11, 708765 (2021).
7. Hernández, J., Thompson, I. M. Prostate‐specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 101(5), 894-904 (2004).
8. Razmi, N., Hasanzadeh, M. Current advancement on diagnosis of ovarian cancer using biosensing of CA 125 biomarker: Analytical approaches. TrAC trends in analytical chemistry. 108, 1-12 (2018).
9. Ridker, P. M., Hennekens, C. H., Buring, J. E. et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England journal of medicine. 342(12), 836-843 (2000).
10. Moraes, T. P. D., Fortes, P. C. N., Ribeiro, S. C., et al. Comparative analysis of lipid and glucose metabolism biomarkers in non-diabetic hemodialysis and peritoneal dialysis patients. Brazilian journal of nephrology.33, 173-179 (2011).
11. Krentz, A. J., Hompesch, M. Glucose: Archetypal biomarker in diabetes diagnosis, clinical management and research. Biomarkers in medicine. 10(11), 1153-1166 (2016).
12. Upadhyay, R. K. Emerging risk biomarkers in cardiovascular diseases and disorders. Journal of lipids. 2015(1), 971453 (2015).
13. Okorie, O. N., Dellinger, P. Lactate: biomarker and potential therapeutic target. Critical care clinic. 27(2), 299-326 (2011).
14. Wu, M., Zhang, Y., Zhang, Y., et al. Imaging-based biomarkers for predicting and evaluating cancer immunotherapy response. Radiology: Imaging Cancer. 1(2), e190031 (2019).
15. Castel, A. D., Befus, M., Willis, S., Griffin, A., et al. Use of the community viral load as a population-based biomarker of HIV burden. Aids, 26(3), 345-353 (2012)
16. Johnson, G., Ferrini, A., Dolan, S. K., et al. Biomarkers for invasive aspergillosis: the challenges continue. Biomarkers in medicine. 8(3), 429-451 (2014).
17. Sciascia, S., Bizzaro, N., Meroni, P. L., et al. Autoantibodies testing in autoimmunity: Diagnostic, prognostic and classification value. Autoimmunity reviews. 22(7), 103356 (2023).
18. Monastero, R. N., Pentyala, S. Cytokines as biomarkers and their respective clinical cutoff levels. International journal of inflammation. 2017(1), 4309485 (2017).
19. Ghisoni, E., Morotti, M., Sarivalasis, A., et al. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach. Nature reviews clinical oncology,.1-17 (2024).
20. Tchounwou, P. B., Yedjou, C. G., Patlolla, A. K., et al. Heavy metal toxicity and the environment. Molecular, Clinical and Environmental Toxicology: Volume 3: Environmental Toxicology. 133–164 (2012).
21. Anwar, W. A., et al. Biomarkers of human exposure to pesticides. Environmental Health Perspectives. 105(suppl 4), 801–806 (1997).
22. Choi, Y. J., Park, M. J., Cho, Y., Kim, J., et al. Screening for RV dysfunction using smartphone ECG analysis app: Validation study with acute pulmonary embolism patients. Journal of clinical medicine. 13(16), 4792 (2024).
23. Fathil, M. F. M., Arshad, M. M., Gopinath, et al. Diagnostics on acute myocardial infarction: Cardiac troponin biomarkers. Biosensors and bioelectronics, 70, 209-220 (2015)
24. Sin, D. D., Vestbo, J. Biomarkers in chronic obstructive pulmonary disease. Proceedings of the American thoracic society. 6(6), 543-545 (2009).
25. Orucevic, A., Chen, J., McLoughlin, J. M., et al. Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer–an institution’s 10‐year experience. The breast journal. 21(2), 147-154 (2015).
26. De Ruijter, W., Westendorp, R. G., Assendelft, W. J., et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. Bmj. 338 (2009).
27. Custodio, A., Feliu, J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Critical reviews in oncology/hematology. 85(1), 45-81 (2013).
28. Ahn, S., Woo, J. W., Lee, K., et al. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. Journal of pathology and translational medicine.54(1), 34-44 (2020).
29. Cheng, L., Lopez-Beltran, A., Massari, F., et al. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Modern pathology. 31(1), 24-38 (2018).
30. Sim, S. C., Ingelman-Sundberg, M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends in pharmacological sciences. 32(2), 72-81 (2011).
31. Sherwani, S. I., Khan, H. A., Ekhzaimy, A., et al. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomarker insights. 11, BMI-S38440 (2016).
32. Ozer, J., Ratner, M., Shaw, M., Bailey, W., et al. The current state of serum biomarkers of hepatotoxicity. Toxicology. 245(3), 194-205 (2008).
33. Zhao, B., Schwartz, L. H., Larson, S. M. Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. Journal of nuclear medicine. 50(2), 239-249 (2009).
34. van Meer, L., Moerland, M., Cohen, A. F., et al. Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development. British journal of clinical pharmacology. 77(6), 947-957 (2014).
35. Gwaltney-Brant, S. Blood and bone marrow toxicity biomarkers. Biomarkers in toxicology (pp. 401-411). Academic Press (2019).
36. Milton, J. N., Gordeuk, V. R., Taylor, J. G., Gladwin, M. T., et al. Prediction of fetal hemoglobin in sickle cell anemia using an ensemble of genetic risk prediction models. Circulation: Cardiovascular genetics. 7(2), 110-115 (2014).
37. Sergeeva, I. A., Christoffels, V. M. Regulation of expression of atrial and brain natriuretic peptide, biomarkers for heart development and disease. Biochimica et Biophysica acta (BBA)-Molecular basis of disease. 1832(12), 2403-2413 (2013).
38. Del Giudice, M., Gangestad, S. W. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. Brain, behavior, and immunity. 70, 61-75 (2018).
39. Elshourbagy, N. A., Meyers, H. V., Abdel-Meguid, S. S. Cholesterol: the good, the bad, and the ugly-therapeutic targets for the treatment of dyslipidemia. Medical principles and practice. 23(2), 99-111 (2014).
40. Khan, H. A., Sobki, S. H., Ekhzaimy, A., et al. Biomarker potential of C-peptide for screening of insulin resistance in diabetic and non-diabetic individuals. Saudi journal of biological sciences. 25(8), 1729-1732 (2018).
41. Landgraf, W., Owens, D. R., Frier, B. M., et al. Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL. Diabetes, obesity and metabolism. 22(3), 315-323 (2020).
42. Lue, L. F., Guerra, A., Walker, D. G. Amyloid beta and tau as Alzheimer’s disease blood biomarkers: promise from new technologies. Neurology and therapy, 6, 25-36 (2017).
43. Ong, F. S., Das, K., Wang, J., et al. Personalized medicine and pharmacogenetic biomarkers: Progress in molecular oncology testing. Expert Review of Molecular Diagnostics. 12(6), 593–602 (2012).
44. Goulart, B. H., Clark, J. W., Pien, H. H., et al. Trends in the use and role of biomarkers in phase I oncology trials. Clinical cancer research, 13(22), 6719-6726 (2007).
45. LeBlanc, G. A., Bain, L. J. Chronic toxicity of environmental contaminants: sentinels and biomarkers. Environmental health perspectives. 105(suppl 1), 65-80 (1997).
46. Sommar, J. N., Hedmer, M., Lundh, T., et al. A. Investigation of lead concentrations in whole blood, plasma and urine as biomarkers for biological monitoring of lead exposure. Journal of exposure science & environmental epidemiology. 24(1), 51-57 (2014).
47. Li, J., Zhu, Y., Shoemake, B., et al. A systematic review of the utility of biomarkers as aids in the early diagnosis and outcome prediction of bovine respiratory disease complex in feedlot cattle. Journal of veterinary diagnostic investigation. 34(4), 577-586 (2022).
48. Aina, O., Bakare, O. O., Fadaka, A. O., et al. Plant biomarkers as early detection tools in stress management in food crops: A review. Planta. 259(3), 60 (2024).
49. Mayeux, R. Biomarkers: potential uses and limitations. NeuroRx, 1, 182-188 (2004)
50. Amur, S., LaVange, L., Zineh, I., et al. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clinical pharmacology & therapeutics. 98(1), 34-46 (2015).
51. Feng, Z., Pepe, M. S. Adding rigor to biomarker evaluations—EDRN experience. Cancer epidemiology, biomarkers & prevention. 29(12), 2575-2582 (2020).
52. Enroth, S., Johansson, Å., Enroth, S. B. et al. Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs. Nature communications. 5(1), 4684 (2014).
53. Srivastava, A., Creek, D. J. Discovery and validation of clinical biomarkers of cancer: a review combining metabolomics and proteomics. Proteomics. 19(10), 1700448 (2019).
54. Xiao, Y., Bi, M., Guo, H., et al. Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis. EBioMedicine. 79 (2022).
55. Montaner, J., Ramiro, L., Simats, A., et al. Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nature Reviews Neurology. 16, 247–264 (2020). https://doi.org/10.1038/s41582-020-0350-6
56. Cheng, F., Su, L., Qian, C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 7(30), 48832 (2016).
57. Mann, M., Kumar, C., Zeng, W. F. et al. Artificial intelligence for proteomics and biomarker discovery. Cell systems. 12(8), 759-770 (2021).
58. Prelaj, A., Miskovic, V., Zanitti, M., et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: A systematic review. Annals of Oncology. 35(1), 29–65 (2024).
59. Collins, D. C., Sundar, R., Lim, J. S. et al. Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics. Trends in pharmacological sciences, 38(1), 25-40 (2017).
60. Cheng, F., Su, L., Qian, C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 7(30), 48832 (2016).
61. Mann, M., Kumar, C., Zeng, W. F. et al. Artificial intelligence for proteomics and biomarker discovery. Cell systems. 12(8), 759-770 (2021).
62. Prelaj, A., Miskovic, V., Zanitti, M., et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: A systematic review. Annals of Oncology. 35(1), 29–65 (2024).
63. Collins, D. C., Sundar, R., Lim, J. S. et al. Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics. Trends in pharmacological sciences, 38(1), 25-40 (2017).